Aberdeen Group (NASDAQ: CRBP) discloses 7.53% Corbus Pharmaceuticals stake

Rhea-AI Filing Summary

Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported that Aberdeen Group plc and its U.S. affiliate abrdn Inc. have become significant shareholders. The filing shows that these related entities beneficially own a total of 1,321,750 shares of Corbus common stock, representing 7.53% of the outstanding shares as of the reported date. Both Aberdeen Group plc (United Kingdom) and abrdn Inc. (United States) report shared voting and dispositive power over all of these shares, with no sole voting or sole dispositive authority.

The securities are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Corbus, consistent with an institutional investment position under Schedule 13G. The filing notes that abrdn Inc. holds more than 5% of this class of stock on behalf of its underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Corbus Pharmaceuticals Holdings, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

21833P301

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 21833P301

1

Names of Reporting Persons

Aberdeen Group plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,321,750.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,321,750.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,321,750.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.53 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 21833P301

1

Names of Reporting Persons

abrdn Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,321,750.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,321,750.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,321,750.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.53 %

12

Type of Reporting Person (See Instructions)

CO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Corbus Pharmaceuticals Holdings, Inc.
(b)	Address of issuer's principal executive offices: 500 RIVER RIDGE DRIVE, NORWOOD, MASSACHUSETTS 02062
Item 2.
(a)	Name of person filing: Aberdeen Group plc abrdn Inc.
(b)	Address or principal business office or, if none, residence: Aberdeen Group plc 1 George Street Edinburgh, United Kingdom EH2 2LL abrdn Inc. 1900 Market Street Suite 200 Philadelphia PA 19103
(c)	Citizenship: Aberdeen Group plc - UNITED KINGDOM abrdn Inc. - UNITED STATES
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 21833P301
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1,321,750
(b)	Percent of class: 7.53 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Aberdeen Group plc - 0 abrdn Inc. - 0
	(ii) Shared power to vote or to direct the vote: Aberdeen Group plc - 1,321,750 abrdn Inc. - 1,321,750
	(iii) Sole power to dispose or to direct the disposition of: Aberdeen Group plc - 0 abrdn Inc. - 0
	(iv) Shared power to dispose or to direct the disposition of: Aberdeen Group plc - 1,321,750 abrdn Inc. - 1,321,750
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Aberdeen Group plc

Signature:	Cara Bird
Name/Title:	Cara Bird / Major Shareholding Reporting Analyst
Date:	01/16/2026

abrdn Inc.

Signature:	Cara Bird
Name/Title:	Cara Bird / Major Shareholding Reporting Analyst
Date:	01/16/2026

Exhibit Information

Aberdeen Group plc abrdn Holdings Limited abrdn Inc. Aberdeen Group plc is the parent company. abrdn Holdings Limited is the intermediate holding company for abrdn Inc. abrdn Inc. beneficially owns on behalf of our underlying clients 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G.

FAQ

What percentage of Corbus Pharmaceuticals (CRBP) does Aberdeen Group plc beneficially own?

The filing states that Aberdeen Group plc and abrdn Inc. together beneficially own 1,321,750 shares of Corbus Pharmaceuticals common stock, representing 7.53% of the outstanding class as of the reported date.

How many Corbus Pharmaceuticals (CRBP) shares are reported as beneficially owned by abrdn Inc.?

abrdn Inc. is reported as beneficially owning 1,321,750 shares of Corbus Pharmaceuticals common stock, the same aggregate amount reported by Aberdeen Group plc, with shared voting and shared dispositive power over these shares.

Do Aberdeen Group plc and abrdn Inc. have sole or shared voting power over CRBP shares?

The filing shows 0 shares with sole voting power and 1,321,750 shares with shared voting power for both Aberdeen Group plc and abrdn Inc. They also report shared dispositive power over the same number of shares.

Is the Aberdeen and abrdn stake in Corbus Pharmaceuticals intended to influence control of the company?

No. The certification states the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose or effect of changing or influencing the control of Corbus Pharmaceuticals.

Who actually holds more than 5% of Corbus Pharmaceuticals shares on behalf of clients?

The exhibit explains that abrdn Inc. beneficially owns on behalf of its underlying clients 5% or greater of the outstanding shares of the reported security class, with Aberdeen Group plc as the parent and abrdn Holdings Limited as the intermediate holding company.

What type of reporting persons are Aberdeen Group plc and abrdn Inc. in this ownership filing?

Aberdeen Group plc is classified as HC (a parent holding company or control person), while abrdn Inc. is classified as CO, IA (a corporation and investment adviser) under the Schedule 13G reporting categories.

What class of Corbus Pharmaceuticals securities is covered in this Schedule 13G?

The filing covers common stock of Corbus Pharmaceuticals Holdings, Inc., with a par value of $0.0001 per share and CUSIP 21833P301.